583 related articles for article (PubMed ID: 34131316)
1. Advancing therapy for osteosarcoma.
Gill J; Gorlick R
Nat Rev Clin Oncol; 2021 Oct; 18(10):609-624. PubMed ID: 34131316
[TBL] [Abstract][Full Text] [Related]
2. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.
Roth M; Linkowski M; Tarim J; Piperdi S; Sowers R; Geller D; Gill J; Gorlick R
Cancer; 2014 Feb; 120(4):548-54. PubMed ID: 24166473
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
4. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
5. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
6. HER2-Targeted Therapy in Osteosarcoma.
Gill J; Hingorani P; Roth M; Gorlick R
Adv Exp Med Biol; 2020; 1257():55-66. PubMed ID: 32483730
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cells in osteosarcoma.
Brown HK; Tellez-Gabriel M; Heymann D
Cancer Lett; 2017 Feb; 386():189-195. PubMed ID: 27894960
[TBL] [Abstract][Full Text] [Related]
8. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
9. Positron Emission Tomography Detects
Butch ER; Mead PE; Amador Diaz V; Tillman H; Stewart E; Mishra JK; Kim J; Bahrami A; Dearling JLJ; Packard AB; Stoddard SV; Vāvere AL; Han Y; Shulkin BL; Snyder SE
Cancer Res; 2019 Jun; 79(12):3112-3124. PubMed ID: 31015228
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
[TBL] [Abstract][Full Text] [Related]
12. Scaffold-based 3D cellular models mimicking the heterogeneity of osteosarcoma stem cell niche.
Bassi G; Panseri S; Dozio SM; Sandri M; Campodoni E; Dapporto M; Sprio S; Tampieri A; Montesi M
Sci Rep; 2020 Dec; 10(1):22294. PubMed ID: 33339857
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma: the state of affairs dictates a change. What do we know?
Kleinerman ES; Mary V; John A
Adv Exp Med Biol; 2014; 804():vii-viii. PubMed ID: 25207354
[No Abstract] [Full Text] [Related]
14. Role of ezrin in osteosarcoma metastasis.
Ren L; Khanna C
Adv Exp Med Biol; 2014; 804():181-201. PubMed ID: 24924175
[TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.
Mohseny AB; Szuhai K; Romeo S; Buddingh EP; Briaire-de Bruijn I; de Jong D; van Pel M; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2009 Nov; 219(3):294-305. PubMed ID: 19718709
[TBL] [Abstract][Full Text] [Related]
16. Advances in emerging drugs for osteosarcoma.
Hattinger CM; Fanelli M; Tavanti E; Vella S; Ferrari S; Picci P; Serra M
Expert Opin Emerg Drugs; 2015 Sep; 20(3):495-514. PubMed ID: 26021401
[TBL] [Abstract][Full Text] [Related]
17. Advances in differentiation therapy for osteosarcoma.
Chen Y; Cao J; Zhang N; Yang B; He Q; Shao X; Ying M
Drug Discov Today; 2020 Mar; 25(3):497-504. PubMed ID: 31499188
[TBL] [Abstract][Full Text] [Related]
18. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
Baranski Z; Booij TH; Cleton-Jansen AM; Price LS; van de Water B; Bovée JV; Hogendoorn PC; Danen EH
J Pathol; 2015 Jul; 236(3):348-59. PubMed ID: 25757065
[TBL] [Abstract][Full Text] [Related]
19. Drugs in early clinical development for the treatment of osteosarcoma.
Heymann MF; Brown HK; Heymann D
Expert Opin Investig Drugs; 2016 Nov; 25(11):1265-1280. PubMed ID: 27633385
[TBL] [Abstract][Full Text] [Related]
20. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.
Lo WW; Wunder JS; Dickson BC; Campbell V; McGovern K; Alman BA; Andrulis IL
Cancer; 2014 Feb; 120(4):537-47. PubMed ID: 24151134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
